Earlier this month, Mesoblast announced that its therapy Ryoncil received a permanent Healthcare Common Procedure Coding System (HCPCS) J-Code from the US Centers for Medicare and Medicaid Services, effective October 1, enabling standardized reimbursement for hospitals and clinics. This formal recognition by CMS is a key step in facilitating broader access for patients and simplifying reimbursement processes for providers, supporting increased adoption of the therapy. We’ll explore how the permanent J-Code recognition for Ryoncil shapes Mesoblast’s investment narrative and future growth prospects.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

What Is Mesoblast's Investment Narrative?

For investors considering Mesoblast, the central argument rests on believing in the company’s ability to translate its scientific innovation into sustained commercial outcomes, particularly through approvals, reimbursement wins, and pipeline expansion. The recent assignment of a permanent J-Code for Ryoncil by CMS is not just a formal milestone but a strong catalyst for near-term growth, potentially accelerating both sales and real-world adoption, strengthening the product’s commercial profile in pediatric SR-aGvHD. This shift meaningfully alters short-term catalysts, with reimbursement hurdles now lower for hospitals and clinics, improving predictability for revenue generation. On the risk side, while the expanded access may ease some commercial execution pressure, Mesoblast still faces significant challenges, including consistent revenue growth, larger losses, ongoing clinical trial costs, and a heavy reliance on future regulatory successes, particularly for label extensions and the Revascor pipeline. The J-Code news meaningfully reweights the risk-reward balance in the short term but long-term profitability remains a core concern. Yet even with this milestone, future revenue still hinges on successful trial outcomes and regulatory progress.

Despite retreating, Mesoblast's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other PerspectivesASX:MSB Community Fair Values as at Oct 2025

Mesoblast’s fair value estimates from 21 Simply Wall St Community members span a vast A$0.18 to A$50, reflecting a broad spectrum of views on the company’s prospects. While a permanent J-Code increases confidence in reimbursement, diverging opinions show how much rides on pivotal trial results and the path to sustained profitability. Check out these different perspectives to see how you compare.

Story Continues

Explore 21 other fair value estimates on Mesoblast - why the stock might be worth less than half the current price!

Build Your Own Mesoblast Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Mesoblast research is our analysis highlighting 2 key rewards that could impact your investment decision. Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments